Ge Long Hui A P P·2025-09-08 00:22Core Viewpoint - CITIC Securities initiates coverage on Yaoshi Bang (9885.HK) with a "Buy" rating, highlighting its strong profitability and growth prospects [1] Group 1: Financial Performance - Yaoshi Bang's revenue is projected to grow from 6.06 billion to 17.904 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 31.1% [1] - The company is expected to achieve revenue and net profit attributable to shareholders of 9.843 billion and 78 million respectively in the first half of 2025, representing year-on-year growth of 11.7% and 258% [1] - Forecasted net profits for 2025-2027 are 148 million, 315 million, and 512 million, with year-on-year growth rates of 393.6%, 112.3%, and 62.7% respectively [1] Group 2: Business Strategy and Market Position - Yaoshi Bang is focusing on the outpatient sinking market, enhancing its self-operated brand and proprietary brand business, which are driving revenue and gross margin improvements [1] - The company is expected to benefit from the steady growth of POCT (Point of Care Testing) devices, achieving synergy among medicine, pharmacy, and testing [1] - Multiple brokerages, including Xinda Securities and Great Wall Securities, maintain a positive outlook on Yaoshi Bang, citing strong growth from its proprietary brand business and a strategic shift from "scale expansion" to "profit enhancement" [2] Group 3: Stock Performance and Market Sentiment - Yaoshi Bang's stock price has increased from 5 HKD to around 11 HKD this year, with a maximum increase of over 120% [2] - The stock is currently stabilizing around 10 HKD, with analysts suggesting that the company is in a phase of shareholder chip exchange, leading to potential short-term volatility [2] - The company's fundamentals are strong, and after completing the chip exchange and stabilizing, there may be opportunities for upward breakthroughs [2]